PepGen Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PEPG Nasdaq 2834 www.pepgen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PepGen Inc.

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - Aug 6th, 2026 5:32 am
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - Aug 6th, 2026 5:30 am
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 20th, 2026 7:35 am
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - May 17th, 2026 10:49 pm
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know - May 13th, 2026 10:00 am
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer - May 12th, 2026 1:30 am
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - Mar 31st, 2026 6:07 pm
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA - Mar 5th, 2026 3:59 am
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% - Dec 10th, 2025 7:55 am
Sarepta's Stock Rises on Positive Updates on DM1 Therapy - Nov 25th, 2025 11:08 am